Adding the investigational advanced breast cancer candidate, abemaciclib, to the already-approved drug fulvestrant, reduced the risk of disease worsening or death for women with hormone-receptor-positive, HER2-negative disease more than adding a placebo, Eli Lilly and Co. reported.